Acadia Pharmaceuticals (ACAD) Research & Development (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Research & Development of $76.9 million for Q1 2026, down 1.78% year-over-year from $78.3 million in Q1 2025, and down 9.31% quarter-over-quarter from $84.8 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Research & Development (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $76.9 million for Q1 2026.
- In Q1 2026, Research & Development fell 1.78% year-over-year to $76.9 million; the TTM figure through Mar 2026 stood at $327.4 million (up 1.73% YoY), while the FY2025 annual figure was $328.8 million, up 8.43% from the prior year.
- Research & Development for Q1 2026 stood at $76.9 million, down from $84.8 million in the prior quarter.
- The five-year high for Research & Development was $157.0 million in Q3 2023, with the low at $58.8 million in Q2 2023.
- The 5-year median for Research & Development is $76.9 million (2026), against an average of $83.7 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 126.17% in 2022, then sank 57.57% in 2024.
- Acadia Pharmaceuticals' Research & Development stood at $75.7 million in 2022, then decreased by 11.88% to $66.7 million in 2023, then soared by 50.93% to $100.7 million in 2024, then fell by 15.86% to $84.8 million in 2025, then decreased by 9.31% to $76.9 million in 2026.
- Business Quant data shows ACAD's Research & Development at $76.9 million in Q1 2026, $84.8 million in Q4 2025, and $87.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 81.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.56 Mn |
| Mar 31, 2026 | 76.87 Mn |
| Dec 31, 2025 | 84.76 Mn |
| Sep 30, 2025 | 87.83 Mn |
| Jun 30, 2025 | 77.95 Mn |
| Mar 31, 2025 | 78.27 Mn |
| Dec 31, 2024 | 100.73 Mn |
| Sep 30, 2024 | 66.61 Mn |
| Jun 30, 2024 | 76.23 Mn |
| Mar 31, 2024 | 59.68 Mn |
| Dec 31, 2023 | 66.74 Mn |
| Sep 30, 2023 | 156.96 Mn |
| Jun 30, 2023 | 58.77 Mn |
| Mar 31, 2023 | 69.14 Mn |
| Dec 31, 2022 | 75.74 Mn |
| Sep 30, 2022 | 81.34 Mn |
| Jun 30, 2022 | 75.65 Mn |
| Mar 31, 2022 | 128.86 Mn |
| Dec 31, 2021 | 66.94 Mn |
| Sep 30, 2021 | 58.57 Mn |